اثر درمانی سلول‌های بنیادی بر کاهش میزان چسبندگی‌های داخل رحمی: مقاله مروری

نوع مقاله : مروری

نویسندگان

1 دانشجوی دکتری تخصصی فیزیولوژی پزشکی، دانشکده پزشکی، دانشگاه علوم پزشکی مشهد، مشهد، ایران.

2 استادیار گروه ژنتیک انسانی، دانشکده پزشکی، دانشگاه علوم پزشکی مشهد، مشهد، ایران.

3 دانشیار گروه بیوشیمی بالینی، دانشکده پزشکی، دانشگاه علوم پزشکی مشهد، مشهد، ایران.

4 استاد گروه فیزیولوژی پزشکی، دانشکده پزشکی، دانشگاه علوم پزشکی مشهد، مشهد، ایران.

چکیده

مقدمه: سندرم آشرمن (AS) یک اختلال اکتسابی و مقاوم به درمان در زنان است که در حال حاضر روش‌های درمانی آن محدود و غیرمؤثر است. درمان‌های مبتنی بر سلول‌های بنیادی اخیراً به روشی جدید برای درمان آسیب‌های بافتی و فیبروز تبدیل شده است. امروزه سلول درمانی به‌عنوان یک استراتژی جدید برای بازسازی و مدیریت اختلالات آندومتر مانند سندرم آشرمن پیشنهاد شده است. مطالعه حاضر با هدف بررسی خلاصه‌ای از پژوهش‌هایی که نقش کلیدی سلول درمانی را در درمان اختلالات و چسبندگی‌های داخل رحمی نشان داده‌اند، انجام شد.
روش‌کار: در این مقاله مروری مقالات مرتبط با نقش سلول‌های بنیادی در پیشگیری و درمان چسبندگی‌های داخل رحمی در پایگاه‌های اطلاعاتی از جمله ISI، Google scholar، PubMed، Scopus و SID با استفاده از کلمات کلیدی Asherman's syndrome، Intrauterine adhesions، Stem cell therapy بدون در نظر گرفتن بازه زمانی مورد جستجو قرار گرفتند. در پایان کار، داده‌های ورودی به‌صورت کیفی بررسی و تحلیل شدند.
یافته‌ها: مطالعات بررسی شده، پیوند سلول‌های بنیادی مختلف از منابع متنوع از جمله مغز استخوان، بافت چربی، مایع آمنیوتیک، جفت و خون قاعدگی را نشان می‌دهند که در منطقه آندومتر رحم سبب بازسازی آندومتر و بازگردانی قدرت باروری در سندرم آشرمن می‌شوند. مطالعات صورت گرفته نشان داده‌اند که پیوند سلول‌های BMSC و MenSC، نه‌تنها در مطالعات حیوانی، بلکه در مطالعات بالینی نیز منجر به بازسازی و شکل‌گیری ساختار بافتی آندومتر آسیب دیده شده است. در مدل‌های پیش بالینی نیز سلول‌های بنیادی مشتق از بافت چربی (ASC)، سلول‌های بنیادی مشتق از مایع آمنیون (AFSC) و سلول‌های بنیادی مشتق از جفت (PSC)، توانسته‌اند از طریق افزایش ضخامت اپی‌تلیال و کاهش میزان ترشح و رسوب کلاژن، نقش مؤثری را در بازسازی و تقویت آندومتر رحم داشته باشند.
نتیجه‌گیری: استفاده از سلول‌های بنیادی می‌تواند نقش مهمی در بازسازی و شکل‌گیری بافت آندومتر رحم داشته باشد و می‌تواند در پیشگیری و درمان چسبندگی‌های داخل رحمی مؤثر واقع شود.

کلیدواژه‌ها

عنوان مقاله [English]

Therapeutic effect of stem cells on reducing intrauterine adhesions

نویسندگان [English]

  • Seyedeh Elnaz Nazari 1
  • Amir Avan 2
  • Seyed Mahdi Hassanian Mehr 3
  • Majid Khazaei 4
1 Ph.D. student of Medical Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
2 Assistant Professor, Department of Human Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
3 Associate Professor, Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
4 Professor, Department of Medical Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
چکیده [English]

Introduction: Asherman's syndrome (AS) is an acquired and refractory disorder in women whose treatments are currently limited and ineffective. Stem cell-based therapies have recently become a new way to treat tissue damage and fibrosis. Cell therapy is now proposed as a new strategy for the reconstruction and management of endometrial disorders such as Asherman syndrome. The present study was performed aimed to review a summary of research showing the key role of cell therapy in the treatment of intrauterine disorders and adhesions. Methods:In this review article, the articles related to the role of stem cells in the prevention and treatment of intrauterine adhesions were searched in databases of ISI, Google scholar, PubMed, Scopus and SID using the keywords of Asherman's syndrome, Intrauterine adhesions, and Stem cell therapy without time limitation. At the end, the input data were qualitatively analyzed.Results: Studies show that stem cell transplants come from a variety of sources, including bone marrow (BMCS), adipose tissue (ASC), amniotic fluid (AFSC), placenta (PSC), and menstrual blood (MenSC) that regenerates the uterine endometrium and restores fertility in Asherman syndrome. Studies have shown that transplantation of BMSCs and MenSCs, not only in animal studies but also in clinical studies, has led to the regeneration and formation of damaged endometrial tissue structure. In preclinical models, Adipose tissue-derived stem cells (ASCs), amniotic fluid-derived stem cells (AFSCs) and placenta-derived stem cells (PSCs) have been able to play an effective role in regenerating and strengthening the uterine endometrium by increasing epithelial thickness and reducing collagen secretion and deposition.
Conclusion: Use of stem cells can play an important role in the regeneration and formation of endometrial tissue of the uterus and thus has beneficial effects in prevention and treatment of intrauterine adhesions.

کلیدواژه‌ها [English]

  • Asherman syndrome
  • Intra uterine adhesion
  • Stem Cell

مراجع

  1. Dreisler E, Kjer JJ. Asherman’s syndrome: current perspectives on diagnosis and management. International journal of women's health 2019; 11:191.
  2. Asherman JG. Traumatic intra‐uterine adhesions. BJOG: An International Journal of Obstetrics & Gynaecology 1950; 57(6):892-6.
  3. Bai X, Liu J, Cao S, Wang L. Mechanisms of endometrial fibrosis and the potential application of stem cell therapy. Discovery medicine 2019; 27(150):267-79.
  4. Hu J, Zeng B, Jiang X. The expression of marker for endometrial stem cell and fibrosis was increased in intrauterine adhesious. International journal of clinical and experimental pathology 2015; 8(2):1525.
  5. March CM. Management of Asherman’s syndrome. Reproductive biomedicine online 2011; 23(1):63-76.
  6. Polishuk WZ, Siew FP, Gordon R, Lebenshart P. Vascular changes in traumatic amenorrhea and hypomenorrhea. International journal of fertility 19771; 22(3):189-92.
  7. Taylor PJ, Cumming DC, Hill PJ. Significance of intrauterine adhesions detected hysteroscopically in eumenorrheic infertile women and role of antecedent curettage in their formation. American journal of obstetrics and gynecology 1981; 139(3):239-42.
  8. Hafizi L, Mahmoudinia M, Noori M. Placenta acreta following hysteroscopic treatment of Asherman syndrome after one uncomplicated cesarean section: a case report. Iran J Obstet Gynecol Infertil 2019; 22(10):86-90.
  9. Rezaei N, Farzi S, Taghinejad H, Shafieian M, Taheri S. Application of stem cells in the treatment of reproductive disorders in men and women. Iran J Obstet Gynecol Infertil 2017; 20:78-96
  10. Cousins FL, Pandoy R, Jin S, Gargett CE. The Elusive Endometrial Epithelial Stem/Progenitor Cells. Frontiers in Cell and Developmental Biology 2021; 9:868.
  11. Gargett CE, Schwab KE, Deane JA. Endometrial stem/progenitor cells: the first 10 years. Human reproduction update 2016; 22(2):137-63.
  12. Min J, Lu N, Huang S, Chai X, Wang S, Peng L, et al. Phenotype and biological characteristics of endometrial mesenchymal stem/stromal cells: A comparison between intrauterine adhesion patients and healthy women. American Journal of Reproductive Immunology 2021; 85(6):e13379.
  13. Wallach EE, Schenker JG, Margalioth EJ. Intrauterine adhesions: an updated appraisal. Fertility and sterility 1982; 37(5):593-610.
  14. Deans R, Abbott J. Review of intrauterine adhesions. Journal of Minimally Invasive Gynecology 2010; 17(5):555-69.
  15. Yasmin H, Nasir A, Noorani KJ. Hystroscopic management of Ashermans syndrome. JPMA 2007.
  16. Conforti A, Alviggi C, Mollo A, De Placido G, Magos A. The management of Asherman syndrome: a review of literature. Reproductive Biology and Endocrinology 2013; 11(1):1-11.
  17. Sugimoto O. Diagnostic and therapeutic hysteroscopy for traumatic intrauterine adhesions. American journal of obstetrics and gynecology 1978; 131(5):539-47.
  18. Mahmoodinia M, Roustaie M. Role of Stem Cells in the Future of Asherman Syndrome Treatment. Sarem Journal of Reproductive Medicine 2019; 4(2):87-92.
  19. Magos A. Hysteroscopic treatment of Asherman's syndrome. Reproductive biomedicine online 2002; 4:46-51.
  20. Fard SA, Gharabaghi PM, Montazeri F, Mashrabi O. Hysteroscopy as a minimally invasive surgery, a good substitute for invasive gynecological procedures. Iranian journal of reproductive medicine 2012; 10(4):377.
  21. Yen CF, Chou HH, Wu HM, Lee CL, Chang TC. Effectiveness and appropriateness in the application of office hysteroscopy. Journal of the Formosan Medical Association 2019; 118(11):1480-7.
  22. Valle RF, Sciarra JJ. Intrauterine adhesions: hysteroscopic diagnosis, classification, treatment, and reproductive outcome. American journal of obstetrics and gynecology 1988; 158(6):1459-70.
  23. March CM, Israel R, March AD. Hysteroscopic management of intrauterine adhesions. American journal of obstetrics and gynecology 1978; 130(6):653-7.
  24. Ismajovich B, Lidor A, Confino E, David MP. Treatment of minimal and moderate intrauterine adhesions (Asherman's syndrome). The Journal of reproductive medicine 1985; 30(10):769-72.
  25. Pellicano M, Bramante S, Cirillo D, Palomba S, Bifulco G, Zullo F, et al. Effectiveness of autocrosslinked hyaluronic acid gel after laparoscopic myomectomy in infertile patients: a prospective, randomized, controlled study. Fertility and sterility 2003; 80(2):441-4.
  26. Guida M, Acunzo G, Di Spiezio Sardo A, Bifulco G, Piccoli R, Pellicano M, et al. Effectiveness of auto‐crosslinked hyaluronic acid gel in the prevention of intrauterine adhesions after hysteroscopic surgery: a prospective, randomized, controlled study. Human Reproduction 2004; 19(6):1461-4.
  27. Yuksel B, Kilic S, Taser F, Pinarli F, Delibasi T. Male fertility preservation, current options with stem cells. Niche 2012; 1:42-5.
  28. Selvi S. Stem cell therapy. International Journal of Advances in Nursing Management 2017; 5(4):361-4.
  29. Benor A, Gay S, DeCherney A. An update on stem cell therapy for Asherman syndrome. Journal of Assisted Reproduction and Genetics 2020; 37:1511-29.
  30. Alawadhi F, Du H, Cakmak H, Taylor HS. Bone marrow-derived stem cell (BMDSC) transplantation improves fertility in a murine model of Asherman's syndrome. PLoS One 2014; 9(5):e96662.
  31. Cervelló I, Gil-Sanchis C, Santamaría X, Cabanillas S, Díaz A, Faus A, et al. Human CD133+ bone marrow-derived stem cells promote endometrial proliferation in a murine model of Asherman syndrome. Fertility and sterility 2015; 104(6):1552-60.
  32. Wang J, Ju B, Pan C, Gu Y, Zhang Y, Sun L, et al. Application of bone marrow-derived mesenchymal stem cells in the treatment of intrauterine adhesions in rats. Cellular Physiology and Biochemistry 2016; 39(4):1553-60.
  33. Tan J, Li P, Wang Q, Li Y, Li X, Zhao D, et al. Autologous menstrual blood-derived stromal cells transplantation for severe Asherman's syndrome. Human Reproduction 2016; 31(12):2723-9.
  34. Santamaria X, Cabanillas S, Cervello I, Arbona C, Raga F, Ferro J, et al. Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman's syndrome and endometrial atrophy: a pilot cohort study. Human Reproduction 2016; 31(5):1087-96.
  35. Gan L, Duan H, Xu Q, Tang YQ, Li JJ, Sun FQ, et al. Human amniotic mesenchymal stromal cell transplantation improves endometrial regeneration in rodent models of intrauterine adhesions. Cytotherapy 2017; 19(5):603-16.
  36. Shao X, Ai G, Wang L, Qin J, Li Y, Jiang H, et al. Adipose-derived stem cells transplantation improves endometrial injury repair. Zygote 2019; 27(6):367-74.
  37. Han X, Ma Y, Lu X, Li W, Xia E, Li TC, et al. Transplantation of Human Adipose Stem Cells Using Acellular Human Amniotic Membrane Improves Angiogenesis in Injured Endometrial Tissue in a Rat Intrauterine Adhesion Model. Cell transplantation 2020; 29:0963689720952055.
  38. Singh N, Shekhar B, Mohanty S, Kumar S, Seth T, Girish B. Autologous bone marrow-derived stem cell therapy for Asherman's syndrome and endometrial atrophy: a 5-year follow-up study. Journal of human reproductive sciences 2020; 13(1):31.
  39. Zhao YX, Chen SR, Huang QY, Chen WC, Xia T, Shi YC, et al. Repair abilities of mouse autologous adipose-derived stem cells and ShakeGel™ 3D complex local injection with intrauterine adhesion by BMP7-Smad5 signaling pathway activation. Stem Cell Research & Therapy 2021; 12(1):1-11.
  40. Ratajczak MZ. A novel view of the adult bone marrow stem cell hierarchy and stem cell trafficking. Leukemia 2015; 29(4):776-82.
  41. Ratajczak MZ, Jadczyk T, Pędziwiatr D, Wojakowski W. New advances in stem cell research: practical implications for regenerative medicine. Pol Arch Med Wewn 2014; 124(7-8):417-26.
  42. Azizi R, Aghebati-Maleki L, Nouri M, Marofi F, Negargar S, Yousefi M. Stem cell therapy in Asherman syndrome and thin endometrium: stem cell-based therapy. Biomedicine & Pharmacotherapy 2018; 102:333-43.
  43. Taylor HS. Endometrial cells derived from donor stem cells in bone marrow transplant recipients. Jama 2004; 292(1):81-5.
  44. Singh N, Mohanty S, Seth T, Shankar M, Bhaskaran S, Dharmendra S. Autologous stem cell transplantation in refractory Asherman's syndrome: A novel cell based therapy. Journal of human reproductive sciences 2014; 7(2):93.
  45. Zhao G, Cao Y, Zhu X, Tang X, Ding L, Sun H, et al. Transplantation of collagen scaffold with autologous bone marrow mononuclear cells promotes functional endometrium reconstruction via downregulating ΔNp63 expression in Asherman’s syndrome. Science China Life Sciences 2017; 60(4):404-16.
  46. Kilic S, Yuksel B, Pinarli F, Albayrak A, Boztok B, Delibasi T. Effect of stem cell application on Asherman syndrome, an experimental rat model. Journal of assisted reproduction and genetics 2014; 31(8):975-82.
  47. Liu Y, Tal R, Pluchino N, Mamillapalli R, Taylor HS. Systemic administration of bone marrow‐derived cells leads to better uterine engraftment than use of uterine‐derived cells or local injection. Journal of cellular and molecular medicine 2018; 22(1):67-76.
  48. Song YT, Liu PC, Tan J, Zou CY, Li QJ, Li-Ling J, et al. Stem cell-based therapy for ameliorating intrauterine adhesion and endometrium injury. Stem Cell Research & Therapy 2021; 12(1):1-14.
  49. Elabd C, Chiellini C, Carmona M, Galitzky J, Cochet O, Petersen R, et al. Human multipotent adipose‐derived stem cells differentiate into functional brown adipocytes. Stem cells 2009; 27(11):2753-60.
  50. Tseng YH, Kokkotou E, Schulz TJ, Huang TL, Winnay JN, Taniguchi CM, et al. New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. Nature 2008; 454(7207):1000-4.
  51. Fraser JK, Wulur I, Alfonso Z, Zhu M, Wheeler ES. Differences in stem and progenitor cell yield in different subcutaneous adipose tissue depots. Cytotherapy 2007; 9(5):459-67.
  52. Sudoma I, Pylyp L, Kremenska Y, Goncharova Y. Application of autologous adipose-derived stem cells for thin endometrium treatment in patients with failed ART programs. J Stem Cell Ther Transplant 2019; 3:001-8.
  53. Monsef F, Artimani T, Alizadeh Z, Ramazani M, Solgi G, Yavangi M, et al. Comparison of the regenerative effects of bone marrow/adipose-derived stem cells in the Asherman model following local or systemic administration. Journal of Assisted Reproduction and Genetics 2020; 37(8):1861-8.
  54. Oliveira MS, Barreto-Filho JB. Placental-derived stem cells: culture, differentiation and challenges. World journal of stem cells 2015; 7(4):769.
  55. Parolini O, Alviano F, Bagnara GP, Bilic G, Bühring HJ, Evangelista M, et al. Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells. Stem cells 2008; 26(2):300-11.
  56. Evangelista M, Soncini M, Parolini O. Placenta-derived stem cells: new hope for cell therapy?. Cytotechnology 2008; 58(1):33-42.
  57. Yu J, Zhang W, Huang J, Gou Y, Sun C, Wu B, et al. Treatment of Intrauterine Adhesions with Human Amnion Mesenchymal Stromal Cells (hAMSCs) on Promoting Endometrial Regeneration and Repair Via Notch Signaling Pathway Regulation; 2020.
  58. Li B, Zhang Q, Sun J, Lai D. Human amniotic epithelial cells improve fertility in an intrauterine adhesion mouse model. Stem cell research & therapy 2019; 10(1):1-14.
  59. Rossignoli F, Caselli A, Grisendi G, Piccinno S, Burns JS, Murgia A, et al. Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood. BioMed research international 2013; 2013.
  60. Patel AN, Park E, Kuzman M, Benetti F, Silva FJ, Allickson JG. Multipotent menstrual blood stromal stem cells: isolation, characterization, and differentiation. Cell transplantation 2008; 17(3):303-11.
  61. Liu T, Huang Y, Zhang J, Qin W, Chi H, Chen J, et al. Transplantation of human menstrual blood stem cells to treat premature ovarian failure in mouse model. Stem cells and development 2014; 23(13):1548-57.
  62. Zheng SX, Wang J, Wang XL, Ali A, Wu LM, Liu YS. Feasibility analysis of treating severe intrauterine adhesions by transplanting menstrual blood-derived stem cells. International journal of molecular medicine 2018; 41(4):2201-12.
  63. Hu J, Song K, Zhang J, Zhang Y, Tan BZ. Effects of menstrual blood‑derived stem cells on endometrial injury repair. Molecular medicine reports 2019; 19(2):813-20.
  64. Chen L, Guo L, Chen F, Xie Y, Zhang H, Quan P, et al. Transplantation of menstrual blood-derived mesenchymal stem cells (MbMSCs) promotes the regeneration of mechanical injuried endometrium. American Journal of Translational Research 2020; 12(9):4941.
  65. Chang QY, Zhang SW, Li PP, Yuan ZW, Tan JC. Safety of menstrual blood-derived stromal cell transplantation in treatment of intrauterine adhesion. World journal of stem cells 2020; 12(5):368.
  66. Gosden CM. Amniotic fluid cell types and culture. British medical bulletin 1983; 39(4):348-54.
  67. Kim J, Lee Y, Kim H, Hwang KJ, Kwon HC, Kim SK, et al. Human amniotic fluid‐derived stem cells have characteristics of multipotent stem cells. Cell proliferation 2007; 40(1):75-90.
  68. Prusa AR, Marton E, Rosner M, Bernaschek G, Hengstschläger M. Oct‐4‐expressing cells in human amniotic fluid: a new source for stem cell research?. Human reproduction 2003; 18(7):1489-93.
  69. Tsai MS, Lee JL, Chang YJ, Hwang SM. Isolation of human multipotent mesenchymal stem cells from second‐trimester amniotic fluid using a novel two‐stage culture protocol. Human reproduction 2004; 19(6):1450-6.
  70. Bollini S, Cheung KK, Riegler J, Dong X, Smart N, Ghionzoli M, et al. Amniotic fluid stem cells are cardioprotective following acute myocardial infarction. Stem cells and development 2011; 20(11):1985-94.
  71. Elias M, Hoover J, Nguyen H, Reyes S, Lawton C, Borlongan CV. Stroke therapy: the potential of amniotic fluid-derived stem cells. Future neurology 2015; 10(4):321-6.
  72. Rodrigues MT, Lee BK, Lee SJ, Gomes ME, Reis RL, Atala A, et al. The effect of differentiation stage of amniotic fluid stem cells on bone regeneration. Biomaterials 2012; 33(26):6069-78.
  73. Queckbörner S, Davies LC, von Grothusen C, Santamaria X, Simón C, Gemzell‐Danielsson K. Cellular therapies for the endometrium: An update. Acta obstetricia et gynecologica Scandinavica 2019; 98(5):672-7.
  74. Zhao Y, Luo Q, Zhang X, Qin Y, Hao J, Kong D, et al. Clinical Efficacy and Safety of Stem Cell-Based Therapy in Treating Asherman Syndrome: A System Review and Meta-Analysis. Stem cells international 2020; 2020.
مجله زنان، مامایی و نازایی ایران
دوره 25، شماره 5
مرداد 1401
صفحه 96-108

فایل ها

هم رسانی

ارجاع به این مقاله

آمار